Dermatol. praxi. 2010;4(4):208-214

Dermatology treatment in pregnancy

MUDr.Zuzana Nevoralová
Kožní oddělení nemocnice v Jihlavě

Dermatovenereologists are often faced with the problem of local and systemic drugs administration to the pregnant woman. The

physician´s responsibility is to be aware of the potential risk of prescribing a specific therapeutic agent, to inform the mother of this

risk, and to administer the most suitable drug for diagnosis. The purpose of this article is to provide guidelines of basic drug administration

to the pregnant woman.

Keywords: pregnancy, risk, dermatovenereologic treatment, local therapy, systemic therapy

Published: December 10, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nevoralová Z. Dermatology treatment in pregnancy. Dermatol. praxi. 2010;4(4):208-214.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Shepard Th. Teratogenicity of therapeutic agents. Curr Probl Pediatr 1979; 10: 5-42. Go to original source... Go to PubMed...
    2. Roztočil A. Léky v těhotenství. In: Roztočil A. Porodnictví. Vydání první, 2001. 106-108.
    3. Council on Scientific Affairs. Effects of toxic chemicals on the reproductive system. JAMA 1985; 253: 3431-3437. Go to original source...
    4. Suchopár J. Léky v těhotenství. PANAX, 13-70.
    5. Donna L, Stockton MD, Paller AS. Drug administration to the pregnant or lactating woman: A reference guide for dermatologists. J Am Acad Dermatol 1990; 23(1): 87-103. Go to original source... Go to PubMed...
    6. Nevoralová Z. Lokální léčba akné. Referátový výběr z dermatologie 2010; 52(Speciál I): 46-54.
    7. Zip C. A practical guide to dermatological drug use in pregnancy. Skin Therapy Letter. com 2006; 11(4).
    8. Navare-Belhanssen C, Blanchet P, Hillaire-Buys D, Sarda P, Blayac JP. Multiple congenital malformations associated with topical tretinoin, Ann Pharmacother 1998; 32(4): 505-506. Go to original source... Go to PubMed...
    9. Colley SM, Walpole I, Fabian VA, Kakulas BA. Topical tretinoin and fetal malformations. Med J Aust 1998; 168(9): 467. Go to original source... Go to PubMed...
    10. Briggs GG, Freeman RK, Yakke SJ. Drugs in Pregnancy and Lactation. 7th ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2005.
    11. Rothman KF, Pochi PE. Use of oral and topical agents for acne in pregnancy. J Am Acad Dermatol 1988; 19(3): 431-433. Go to original source... Go to PubMed...
    12. Kallen BA, Otterblad Olausson P, Danielsson BR. Is erythromycin therapy teratogenic in humans? Reprod Toxicol 2005; 20(2): 209-214. Go to original source... Go to PubMed...
    13. Kallen BA, Otterblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 2003; 17(3): 255-261. Go to original source... Go to PubMed...
    14. Nevoralová Z. Zevní léčba v těhotenství. Referátový výběr z dermatovenerologie 2009; 51(1): 86-88.
    15. Katz VL, Thorp JM Jr, Bowes WA Jr. Severe symmetric intrauterine growth retardation associated with the topical use of trimacinolone. Am J Obstet Gynecol 1990; 162(2): 396-397. Go to original source... Go to PubMed...
    16. Ettler K. Zpráva z 13. mítingu Evropského dermatologického fóra, Lucern, 22.-23. 1. 2010. Čes-slov Derm 2010; 85(2): 116-118.
    17. Tauscher AE, Fleischer AB Jr, Phelps KC, Feldman SR. Psoriasis and pregnancy. J Cutan Med Surg 2002; 6(6): 561-570. Go to original source... Go to PubMed...
    18. Gunnarskog JG, Kallen AJ, Lindelof BG, Sigurgeirsson B. Psoralen photochemotherapy (PUVA) for the treatment of psoriasis. Arch dermatol 1991; 127(3): 347-350. Go to PubMed...
    19. Stern RS, Lange R. Outcomes of pregnancies among women and partners of men with a history of exposurebto methoxsalen photochemotherapy (PUVA) for the treatment of psoriasis. Arch Dermatol 1991; 127(3): 347-350. Go to original source... Go to PubMed...
    20. Smith GH, Anstey AV, Barker JNWN, et al. British Association of Dermatologists´guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019. Go to original source... Go to PubMed...
    21. Osting VC, Carter JD. A safety assessment of tumour necrosis factor antagonists during pregnancy. Exp Opin Drug Saf 2010; 9(3): 421-429. Go to original source... Go to PubMed...
    22. Johnson DL, et al. Pregnancy outcomes for women exposed to adalimumab: OTIS Autoimmune Diseases in Pregnancy Project. Arthritis Rheum 2008; 58(9 Suppl): Abstract 1388. Go to original source...
    23. Johnson DL, et al. Pregnancy outcomes for women exposed to etanercept: OTIS Autoimmune Diseases in Pregnancy Project. Arthritis Rheum 2008; 58(9 Suppl): Abstract 1387.
    24. Ettler K. Individualizace léčby zlepšuje výsledky (zpráva z kongresu, ,Pokrok a příslib" v Madridu ve dnech 4.-6. 2. 2010. Referátový výběr z dermatovenerologie 2010; 52(1): 82-86.
    25. Nevoralová Z. Kožní choroby v těhotenství. Referátový výběr z dermatovenerologie 2005; 47(2): 15-17.
    26. Carmichael SL, Shaw GM. Maternal corticosteroid use and risk of selected congenital anomalies. Am J Med Genet 1999; 86(3): 242-244. Go to original source... Go to PubMed...
    27. Rodriquez-Pinilla E, Martinez-Frias ML. Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology 1998; 58(1): 2-5. Go to original source... Go to PubMed...
    28. Nevoralová Z. Vulvární choroby v těhotenství. Referátový výběr z dermatovenerologie 2010; 52(1): 80-81.
    29. Stone KM, Reiff-Eldridge R, White AD, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 1984-1999. Birth Defects Res A Clin Mol Teratol 2004; 70: 201-207. Go to original source... Go to PubMed...
    30. Diagnostika a terapie infekcí vyvolávaných viry herpes simplex a varicella-zoster, Farmakoterapeutické informace 2010; 7-8: 1-4.
    31. Maw RD. Treatment of external genital warts with 5% imiquimod cream during pregnancy: a case report. BJOG 2004; 111(12): 1475. Go to original source... Go to PubMed...
    32. Einarson A, Costel A, Kalra S, Rouleau M, Koren G. The use of topical 5% imiquimod during pregnancy: a case series. Reprod Toxicol 2006; 21(1): 1-2. Go to original source... Go to PubMed...
    33. Karol MD, Conner CS, Watanabe AS, Murphey KJ. Podophyllum: suspected teratogenicity from topical application. Clin Toxicol 1980; 16(3): 283-286. Go to original source... Go to PubMed...
    34. Chamberlain MJ, Reynolds AL, Yeoman WB. Medical memoranda. Toxic effect of podophyllum application in pregnancy. Br Med J 1972; 3(823): 391-392. Go to original source... Go to PubMed...
    35. Pursley TJ, Blomquist IK, Abraham J, Anderses HF, Bartley JA. Fluconazol-induced congenital anomalies in three infants. Clin Infect Dis 1996; 22(2): 336-340. Go to original source... Go to PubMed...
    36. Štork J. Pohlavně přenosné infekce a nemoci genitálu. In: Štork J, a kol. Dermatovenerologie. 1. vydání. Galén 2008: 442.

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.